Conflicts of interest among authors of clinical practice guidelines for glycemic control in type 2 diabetes mellitus.

ABSTRACT:

Background

Conflict of interest (COI) is an important potential source of bias in the development of clinical practice guidelines (CPGs).

Objectives

To examine rates of disclosure of COI, including financial interests in companies that manufacture drugs that are recommended in CPGs on glycemic control in type 2 diabetes mellitus, and to explore the relationship between recommendations for specific drugs in a guideline and author COI.

Methods

We identified a cohort of relevant guidelines from the National Guideline Clearinghouse (NGC) and abstracted COI disclosures from all guideline authors for this observational, cross-sectional study. We determined which hypoglycemic drugs were recommended in each guideline, and explored the relationship between specific disclosures

SUBMITTER: Norris SL 

PROVIDER: S-EPMC3796568 | biostudies-literature | 2013

REPOSITORIES: biostudies-literature